CHOICE OF AN ANTIHYPERTENSIVE DRUG AND PREVENTION OF RENAL LESION IN HYPERTENSION IN THE LIGHT OF NEW EUROPEAN GUIDELINES


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper considers current approaches to choosing an antihypertensive drug to prevent renal lesion and to improve prognosis, which are relied on evidence-based information and experts’ opinion laid down in the new variant of the European clinical guidelines.

Full Text

Restricted Access

About the authors

S. Gilyarevsky

Russian Medical Academy of Postgraduate Education; N.V. Sklifosovsky Research Institute of Emergency Care

Email: sgilarevsky@rambler.ru

M. Golshmld

Russian Medical Academy of Postgraduate Education

I. Kuzmina

N.V. Sklifosovsky Research Institute of Emergency Care

References

  1. Diercks G., vanBoven A., Hillege J. et al. The importance of microalbuminuria as a cardiovascular risk indicator: a review // Can. J. Cardiol. - 2002; 18: 525-35.
  2. Kovesdy C., Lott E., Lu J. et al. Outcomes associated with microalbuminuria: effect modification by chronic kidney disease // J. Am. Coll. Cardiol. - 2013; 61: 1626-33.
  3. Klausen K., Borch-Johnsen K., Feldt-Rasmussen B. et al. Very low levels of microalbuminuriaare associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes // Circulation. -2004; 110: 32-5.
  4. Gerstein H., Mann J., Yi Q. et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondi- abetic individuals // JAMA. - 2001; 286: 421-6.
  5. Arnlov J., Evans J., Meigs J. et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study // Circulation. - 2005; 112: 969-75.
  6. Zoccali C., Mallamaci F. Albuminuria in the normal range: the lower is not the better // J. Am. Coll. Cardiol. - 2013; 61: 1634-6.
  7. Mann J., Schmieder R., McQueen M. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial // Lancet. - 2008; 372: 547-53.
  8. Kidney Disease Improving Global Outcomes. Clinical practice guideline for the management of blood pressure in chronic kidney disease // Kidney Int. Suppl. - 2013; 2: 337-414.
  9. Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertens. - 2013; 31: 1281-357.
  10. Lea J., Greene T., Hebert L. et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension // Arch. Int. Med. - 2005; 165: 947-53.
  11. de Zeeuw D., Remuzzi G., Parving H. et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy // Circulation. - 2004; 110: 921-7.
  12. Schmieder R., Mann J., Schumacher H. et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease // Am. Soc. Nephrol. - 2011; 22: 1353-64.
  13. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial // Lancet. - 2007; 370: 829-40.
  14. Mogensen C. Urinary albumin excretion in early and long-term juvenile diabetes // Scand. J. Clin. Lab. Invest. - 1971; 28: 183-93.
  15. Viberti G., Hill R., Jarrett R. et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus // Lancet. - 1982; 1: 1430-2.
  16. de Zeeuw D., Parving H., Henning R. Microalbuminuria as an early marker for cardiovascular disease // J. Am. Soc. Nephrol. - 2006; 17: 2100-5.
  17. Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertens. - 2007; 25: 1105-87.
  18. Standards of medical care in diabetes - 2009 // Diabetes Care. - 2009; 32 (1): 13-61.
  19. Brenner B., Cooper M., de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy // N. Engl. J. Med. - 2001; 345: 861-9.
  20. Lewis E., Hunsicker L., Clarke W. et al. Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes // N. Engl. J. Med. - 2001; 345: 851-60.
  21. Ruggenenti P., Fassi A., Ilieva A. et al. Preventing microalbuminuria in type 2 diabetes // N. Engl. J. Med. - 2004; 351: 1941-51.
  22. Haller H., Ito S., Izzo J. et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes // N. Engl. J. Med. - 2011; 364: 907-17.
  23. FDA Drug Safety Communication: Safety Review Update of Benicar (olmesartan) and cardiovascular events. [4/14/2011]. URL: www.fda.gov/Drugs/ DrugSafety/ucm251268.htm
  24. Savarese G., Costanzo P., Cleland J. et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure // J. Am. Coll. Cardiol. - 2013; 61: 131-42.
  25. Moher D., Liberati A., Tetzlaff J. et al. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement // J. Clin. Epidemiol. - 2009; 62: 1006-12.
  26. van Vark L., Bertrand M., Akkerhuis K. et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients // Eur. Heart. J. - 2012; 33: 2088-97.
  27. Lv J., Perkovic V., Foote C. et al. Antihypertensive agents for preventing diabetic kidney disease // Cochrane Database Syst. Rev. - 2012; 12: CD004136. doi: 10.1002/14651858.CD004136.pub3.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies